As Tokyo Regulators Open More To Global Clinical Trial Data, Some Japanese Drug Outfits Move West To Expand
This article was originally published in PharmAsia News
Executive Summary
Leaders of the India-based Veeda Clinical Research said that by placing a bridging study leg in a clinical trial program early on time lags that often exist between regulatory agencies in the West and in Asia can be further reduced. That strategy can also expedite a drug's entry into other markets and thus benefit both patients and the pharmaceutical companies behind the new products